Design of peptide immunotherapies for MHC class-II-associated autoimmune disorders

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Fridkis Hareli, Masha ^a  

^a ATR LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANACIN; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLATIRAMER; GLUCOCORTICOID; GOLD SALT; HYDROXYCHLOROQUINE; IBUPROFEN; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; INFLIXIMAB; INSULIN; INSULIN DETEMIR; METHOTREXATE; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PRAMLINTIDE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; SULINDAC; UNINDEXED DRUG; HLA ANTIGEN CLASS 2; IMMUNOLOGICAL ADJUVANT; PEPTIDE;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE UVEITIS; BARE LYMPHOCYTE SYNDROME; BLEEDING; CARTILAGE DEGENERATION; CELIAC DISEASE; COMPETITIVE INHIBITION; CYTOKINE PRODUCTION; DRUG EFFICACY; HEARTBURN; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOHISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LYMPH NODE; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE SCLEROSIS; NONHUMAN; PANCREAS TRANSPLANTATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; ULCER; UNSPECIFIED SIDE EFFECT; ANIMAL; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; AUTOIMMUNE DISEASES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; PEPTIDES;

EID: 84890051813     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/826191     Document Type: Review

References (58)

1. Rothbard J. B., Gefter M. L., Interactions between immunogenic peptides and MHC proteins. Annual Review of Immunology 1991 9 527 565 2-s2.0-0025911632
2. Gebe J. A., Swanson E., Kwok W. W., HLA class II peptide-binding and autoimmunity. Tissue Antigens 2002 59 2 78 87 2-s2.0-0036016258 10.1034/j.1399-0039.2002.590202.x (Pubitemid 34620547)
3. Sakai K., Zamvil S. S., Mitchell D. J., Hodgkinson S., Rothbard J. B., Steinman L., Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins. Proceedings of the National Academy of Sciences of the United States of America 1989 86 23 9470 9474 2-s2.0-0024380896 10.1073/pnas.86.23.9470 (Pubitemid 20010448)
4. Hurtenbach U., Lier E., Adorini L., Nagy Z. A., Prevention of autoimmune diabetes in non-obese diabetic mice by treatment with a class II major histocompatibility complex-blocking peptide. Journal of Experimental Medicine 1993 177 5 1499 1504 2-s2.0-0027468566 (Pubitemid 23117142)
5. Fairchild P. J., Thorpe C. J., Travers P. J., Wraith D. C., Modulation of the immune response with T-cell epitopes: the ultimate goal for specific immunotherapy of autoimmune disease. Immunology 1994 81 4 487 496 2-s2.0-0028049674 (Pubitemid 24246494)
6. Brocke S., Gijbels K., Allgretta M., Ferber I., Piercy C., Blankenstein T., Martin R., Utz U., Karin N., Mitchell D., Veromaa T., Waisman A., Gaur A., Conlon P., Ling N., Fairchild P. J., Wraith D. C., O'Garra A., Fathman C. G., Steinman L., Treatment of experimental encephalomyelitis with a peptide analogue myelin basic protein. Nature 1996 379 6563 343 346 2-s2.0-0030069797 10.1038/379343a0 (Pubitemid 26033076)
7. Teitelbaum D., Meshorer A., Hirshfeld T., Arnon R., Sela M., Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. European Journal of Immunology 1971 1 4 242 248 2-s2.0-0015103005
8. McDevitt H. O., Sela M., Genetic control of the antibody response. I. Demonstration of determinant-specific differences in response to synthetic polypeptide antigens in two strains of inbred mice. Journal of Experimental Medicine 1965 122 3 517 531 2-s2.0-0013798175
9. McDevitt H. O., Sela M., Genetic control of the antibody response. II. Further analysis of the specificity of determinant-specific control, and genetic analysis of the response to (H,G)-A-L in CBA and C57 mice. Journal of Experimental Medicine 1967 126 5 969 978 2-s2.0-0014152299
10. Teitelbaum D., Webb C., Meshorer A., Arnon R., Sela M., Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in Guinea pigs and rabbits with bovine and human basic encephalitogen. European Journal of Immunology 1973 3 5 273 279 2-s2.0-0015795775
11. Bornstein M. B., Miller A., Slagle S., A pilot trial of COP 1 in exacerbating-remitting multiple sclerosis. The New England Journal of Medicine 1987 317 7 408 414 2-s2.0-0023248694 (Pubitemid 17131177)
12. Johnson K. P., Brooks B. R., Cohen J. A., Ford C. C., Goldstein J., Lisak R. P., Myers L. W., Panitch H. S., Rose J. W., Schiffer R. B., Vollmer T., Weiner L. P., Wolinsky J. S., Bird S. J., Kolson D. L., Gonzalez-Scarano F., Brennan D., Mandler R. N., Rosenberg G. A., Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo controlled trial. Neurology 1995 45 7 1268 1276 2-s2.0-0029082566
13. Johnson K. P., Brooks B. R., Cohen J. A., Ford C. C., Goldstein J., Lisak R. P., Myers L. W., Panitch H. S., Rose J. W., Schiffer R. B., Vollmer T., Weiner L. P., Wolinsky J. S., Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998 50 3 701 708 2-s2.0-6844254570
14. Fridkis-Hareli M., Teitelbaum D., Gurevich E., Pecht I., Brautbar C., Oh Joong Kwon O. J. K., Brenner T., Arnon R., Sela M., Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells-specificity and promiscuity. Proceedings of the National Academy of Sciences of the United States of America 1994 91 11 4872 4876 2-s2.0-0028340163 10.1073/pnas.91.11.4872 (Pubitemid 24177752)
15. Ben-Nun A., Mendel I., Bakimer R., Fridkis-Hareli M., Teitelbaum D., Arnon R., Sela M., Kerlero de Rosbo N., The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. Journal of Neurology 1996 243 4, supplement 1 S14 S22 2-s2.0-0029986881
16. Teitelbaum D., Fridkis-Hareli M., Arnon R., Sela M., Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. Journal of Neuroimmunology 1996 64 2 209 217 2-s2.0-0029916716 10.1016/0165-5728(95)00180-8 (Pubitemid 26094636)
17. Duda P. W., Schmied M. C., Cook S. L., Krieger J. I., Hafler D. A., Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. The Journal of Clinical Investigation 2000 105 7 967 976 2-s2.0-0034041863 (Pubitemid 30203069)
18. Duda P. W., Krieger J. I., Schmied M. C., Balentine C., Hafler D. A., Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate. The Journal of Immunology 2000 165 12 7300 7307 2-s2.0-0034671576 (Pubitemid 32001210)
19. Fridkis-Hareli M., Teitelbaum D., Arnon R., Sela M., Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major histocompatibility complex molecules on living antigen-presenting cells. Cellular Immunology 1995 163 2 229 236 2-s2.0-0029071717 10.1006/cimm.1995.1121
20. Fridkis-Hareli M., Teitelbaum D., Pecht I., Arnon R., Sela M., Binding of copolymer 1 and myelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells. International Immunology 1997 9 7 925 934 2-s2.0-0030924970 10.1093/intimm/9.7.925 (Pubitemid 27277737)
21. Fusco C., Andreone V., Coppola G., Luongo V., Guerini F., Pace E., Florio C., Pirozzi G., Lanzillo R., Ferrante P., Vivo P., Mini M., Macrì M., Orefice G., Lombardi M. L., HLA-DRBI 1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis. Neurology 2001 57 11 1976 1979 2-s2.0-0035846467 (Pubitemid 33126861)
22. Fridkis-Hareli M., Stern J. N. H., Fugger L., Strominger J. L., Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses. Human Immunology 2001 62 8 753 763 2-s2.0-0034894930 10.1016/S0198-8859(01)00279-8 (Pubitemid 32703342)
23. Fridkis-Hareli M., Strominger J. L., Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. The Journal of Immunology 1998 160 9 4386 4397 2-s2.0-0032080646 (Pubitemid 28217296)
24. Fridkis-Hareli M., Neveu J. M., Robinson R. A., Lane W. S., Gauthier L., Wucherpfennig K. W., Sela M., Strominger J. L., Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. The Journal of Immunology 1999 162 8 4697 4704 2-s2.0-0033561726 (Pubitemid 29314870)
25. Fridkis-Hareli M., Rosloniec E. F., Fugger L., Strominger J. L., Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses. Human Immunology 2000 61 7 640 650 2-s2.0-0033945126 10.1016/S0198-8859(00)00126-9 (Pubitemid 30452557)
26. Fridkis-Hareli M., Rosloniec E. F., Fugger L., Strominger J. L., Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones. Proceedings of the National Academy of Sciences of the United States of America 1998 95 21 12528 12531 2-s2.0-0032514714 10.1073/pnas.95.21.12528 (Pubitemid 28483798)
27. Aharoni R., Teitelbaum D., Sela M., Arnon R., Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America 1997 94 20 10821 10826 2-s2.0-0030987548 10.1073/pnas.94.20.10821 (Pubitemid 27430819)
28. Stern J. N. H., Illés Z., Reddy J., Keskin D. B., Sheu E., Fridkis-Hareli M., Nishimura H., Brosnan C. F., Santambrogio L., Kuchroo V. K., Strominger J. L., Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms. Proceedings of the National Academy of Sciences of the United States of America 2004 101 32 11743 11748 2-s2.0-4143124536 10.1073/pnas.0403832101 (Pubitemid 39095366)
29. Fridkis-Hareli M., Aharoni R., Teitelbaum D., Arnon R., Sela M., Strominger J. L., Binding of random copolymers of three amino acids to class II MHC molecules. International Immunology 1999 11 5 635 641 2-s2.0-0032958107 10.1093/intimm/11.5.635 (Pubitemid 29237755)
30. Fridkis-Hareli M., Santambrogio L., Stern J. N. H., Fugger L., Brosnan C., Strominger J. L., Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis. The Journal of Clinical Investigation 2002 109 12 1635 1643 2-s2.0-0036086944 10.1172/JCI200215402 (Pubitemid 34663526)
31. Lalive P. H., Neuhaus O., Benkhoucha M., Burger D., Hohlfeld R., Zamvil S. S., Weber M. S., Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs 2011 25 5 401 414 2-s2.0-79953890862 10.2165/11588120-000000000-00000
32. Kovalchin J., Krieger J., Genova M., Kawamoto N., Augustyniak M., Collins K., Bloom T., Masci A., Hittinger T., Dufour I., Strominger J. L., Zanelli E., Macrophage-specific chemokines induced via innate immunity by amino acid copolymers and their role in EAE. PLoS ONE 2011 6 12 2-s2.0-83455205820 10.1371/journal.pone.0026274 e26274
33. Kawamoto N., Ohnishi H., Kondo N., Strominger J. L., The role of dendritic cells in the generation of CD4(+) CD25(HI) Foxp3(+) T cells induced by amino acid copolymers. International Immunology 2013 25 53 65
34. Koenig P. A., Spooner E., Kawamoto N., Strominger J. L., Ploegh H. L., Amino acid copolymers that alleviate experimental autoimmune encephalomyelitis in vivo interact with heparan sulfates and glycoprotein 96 in APCs. The Journal of Immunology 2013 191 208 216
35. Yin H., Vistica B. P., Chan C.-C., Strominger J. L., Gery I., Inhibition of experimental autoimmune uveitis by amino acid copolymers. Journal of Neuroimmunology 2009 215 1-2 43 48 2-s2.0-70349739585 10.1016/j.jneuroim.2009. 08.002
36. Martin S., Against the grain: an overview of celiac disease. Journal of the American Academy of Nurse Practitioners 2008 20 5 243 250 2-s2.0-43049133799 10.1111/j.1745-7599.2008.00314.x
37. Sollid L. M., Jabri B., Celiac disease and transglutaminase 2: a model for posttranslational modification of antigens and HLA association in the pathogenesis of autoimmune disorders. Current Opinion in Immunology 2011 23 6 732 738 2-s2.0-82955250010 10.1016/j.coi.2011.08.006
38. Venhoff N., Emmerich F., Neagu M., Salzer U., Koehn C. C., Driever S., Kreisel W., Rizzi M., The role of HLA DQ2 and DQ8 in dissecting celiac-like disease in common variable immunodeficiency. Journal of Clinical Immunology 2013 33 909 916
39. Sewell K. L., Trentham D. E., Pathogenesis of rheumatoid arthritis. The Lancet 1993 341 8840 283 286 2-s2.0-0027463331 10.1016/0140-6736(93)92627-6 (Pubitemid 23038035)
40. Todd J. A., Acha-Orbea H., Bell J. I., Chao N., Fronek Z., Jacob C. O., McDermott M., Sinha A. A., Timmerman L., Steinman L., McDevitt H. O., A molecular basis for MHC class II-associated autoimmunity. Science 1988 240 4855 1003 1009 2-s2.0-0023912807
41. Lanchbury J. S. S., Jaeger E. E. M., Sansom D. M., Hall M. A., Wordsworth P., Stedeford J., Bell J. I., Panayi G. S., Strong primary selection for the Dw4 subtype of DR4 accounts for the HLA-DQw7 association with Felty's syndrome. Human Immunology 1991 32 1 56 64 2-s2.0-0025953648 10.1016/0198-8859(91)90117-R
42. Gregersen P. K., Shen M., Song Q. L., Molecular diversity of HLA-DR4 haplotypes. Proceedings of the National Academy of Sciences of the United States of America 1986 83 8 2642 2646 2-s2.0-3142634609 (Pubitemid 16026939)
43. Nepom G. T., Byers P., Seyfried C., Healey L. A., Wilske K. R., Stage D., Nepom B. S., HLA genes associated with rheumatoid arthritis. Identification of susceptibility alleles using specific oligonucleotide probes. Arthritis and Rheumatism 1989 32 1 15 21 2-s2.0-0024555080 (Pubitemid 19034919)
44. Wordsworth B. P., Lanchbury J. S. S., Sakkas L. I., Welsh K. I., Panayi G. S., Bell J. I., HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proceedings of the National Academy of Sciences of the United States of America 1989 86 24 10049 10053 2-s2.0-0024829522 10.1073/pnas.86.24.10049 (Pubitemid 20030773)
45. Brown J. H., Jardetzky T. S., Gorga J. C., Stern L. J., Urban R. G., Strominger J. L., Wiley D. C., Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993 364 6432 33 39 2-s2.0-0027217789 10.1038/364033a0 (Pubitemid 23233452)
46. Stern L. J., Brown J. H., Jardetzky T. S., Gorga J. C., Urban R. G., Strominger J. L., Wiley D. C., Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994 368 6468 215 221 2-s2.0-0028348369 10.1038/368215a0 (Pubitemid 24108837)
47. Hammer J., Gallazzi F., Bono E., Karr R. W., Guenot J., Valsasnini P., Nagy Z. A., Sinigaglia F., Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. Journal of Experimental Medicine 1995 181 5 1847 1855 2-s2.0-0028952168
48. Woulfe S. L., Bono C. P., Zacheis M. L., Kirschmann D. A., Baudino T. A., Swearingen C., Karr R. W., Schwartz B. D., Negatively charged residues interacting with the p4 pocket confer binding specificity to DRB1 0401. Arthritis and Rheumatism 1995 38 12 1744 1753 2-s2.0-0029564298 10.1002/art.1780381207 (Pubitemid 26010275)
49. Gregersen P. K., Silver J., Winchester R. J., The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis and Rheumatism 1987 30 11 1205 1213 2-s2.0-0023500817 (Pubitemid 18005792)
50. Rowley M., Tait B., Mackay I. R., Collagen antibodies in rheumatoid arthritis: significance of antibodies to denatured collagen and their association with HLA-DR4. Arthritis and Rheumatism 1986 29 2 174 184 2-s2.0-0022921770 (Pubitemid 17022817)
51. Fugger L., Michie S. A., Rulifson I., Lock C. B., Mcdevitt G. S., Expression of HLA-DR4 and human CD4 transgenes in mice determines the variable region β -chain T-cell repertoire and mediates an HLA-DR-restricted immune response. Proceedings of the National Academy of Sciences of the United States of America 1994 91 13 6151 6155 2-s2.0-0028306138 10.1073/pnas.91.13.6151 (Pubitemid 24188301)
52. Rosloniec E. F., Brand D. D., Myers L. K., Whittington K. B., Gumanovskaya M., Zaller D. M., Woods A., Altmann D. M., Stuart J. M., Kang A. H., An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen. Journal of Experimental Medicine 1997 185 6 1113 1122 2-s2.0-0030903740 10.1084/jem.185.6.1113 (Pubitemid 27136803)
53. Dessen A., Lawrence C. M., Cupo S., Zaller D. M., Wiley D. C., X-ray crystal structure of HLA-DR4 (DRA 0101, DRB1 0401) complexed with a peptide from human collagen II. Immunity 1997 7 4 473 481 2-s2.0-0030701632 (Pubitemid 27508699)
54. Wu Y. L., Ding Y. P., Gao J., Tanaka Y., Zhang W., Risk factors and primary prevention trials for type 1 diabetes. International Journal of Biological Sciences 2013 9 666 679
55. Wucherpfennig K. W., Insights into autoimmunity gained from structural analysis of MHC-peptide complexes. Current Opinion in Immunology 2001 13 6 650 656 2-s2.0-0035546216 10.1016/S0952-7915(01)00274-6 (Pubitemid 33000157)
56. Lipton R. B., Drum M., Greeley S. A. W., Danielson K. K., Bell G. I., Hagopian W. A., HLA-DQ haplotypes differ by ethnicity in patients with childhood-onset diabetes. Pediatric Diabetes 2011 12 4 388 395 2-s2.0-79957480700 10.1111/j.1399-5448.2010.00712.x
57. Tollefsen S., Hotta K., Chen X., Simonsen B., Swaminathan K., Mathews I. I., Sollid L. M., Kim C. Y., Structural and functional studies of trans-encoded HLA-DQ2.3 (DQA1 03:01/DQB1 02:01) protein molecule. The Journal of Biological Chemistry 2012 287 17 13611 13619 2-s2.0-84859964381 10.1074/jbc.M111.320374
58. Sabatos-Peyton C. A., Verhagen J., Wraith D. C., Antigen-specific immunotherapy of autoimmune and allergic diseases. Current Opinion in Immunology 2010 22 5 609 615 2-s2.0-78049232715 10.1016/j.coi.2010.08.006